Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bicara Therapeutics

12.42
-0.9300-6.97%
Post-market: 12.840.4200+3.38%16:22 EDT
Volume:746.12K
Turnover:9.60M
Market Cap:675.84M
PE:-0.69
High:14.04
Open:13.49
Low:12.01
Close:13.35
Loading ...

Bicara Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
07 Dec 2024

Bicara Therapeutics Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $42

THOMSON REUTERS
·
06 Dec 2024

Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: A Buy Rating Supported by Innovative Dual-Targeting and Positive Trial Results

TIPRANKS
·
06 Dec 2024

Bicara Therapeutics initiated with a Not Rated at Goldman Sachs

TIPRANKS
·
21 Nov 2024

Bicara Therapeutics Reports Strong IPO and Clinical Advancements

TIPRANKS
·
14 Nov 2024

Stifel Nicolaus Remains a Buy on Bicara Therapeutics Inc. (BCAX)

TIPRANKS
·
13 Nov 2024

Promising Prospects for Bicara Therapeutics: Buy Rating Reinforced by Strong Lead Asset and Strategic Position

TIPRANKS
·
13 Nov 2024

Promising Prospects for Bicara Therapeutics: Buy Rating on Ficerafusp’s Innovative Approach

TIPRANKS
·
13 Nov 2024

Bicara Therapeutics Q3 2024 GAAP EPS $(1.60) Misses $(0.44) Estimate

Benzinga
·
12 Nov 2024

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

GlobeNewswire
·
12 Nov 2024

Five new option listings on October 29th

TIPRANKS
·
29 Oct 2024

Top small-cap stock picks from Morgan Stanley following the group's upgrade to neutral

seekingalpha
·
22 Oct 2024

Opening Day: Another trio of biotech IPOs make Friday debut

TipRanks
·
14 Oct 2024

MBX Biosciences earns Buy rating at three investment firms

Investing.com
·
08 Oct 2024

Stifel Nicolaus Initiates Coverage on Bicara Therapeutics With Buy Rating, $47 Price Target

MT Newswires Live
·
08 Oct 2024

Morgan Stanley Initiates Coverage on Bicara Therapeutics With Overweight Rating

MT Newswires Live
·
08 Oct 2024